Sanofi (SNY) Receives Average Recommendation of “Hold” from Analysts

Sanofi (NYSE:SNY) has been assigned an average rating of “Hold” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $53.50.

Several research analysts have weighed in on the stock. BidaskClub downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Argus restated a “buy” rating and set a $55.00 price objective on shares of Sanofi in a report on Friday, September 1st. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Cowen and Company restated a “market perform” rating and set a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th.

In related news, major shareholder Sanofi acquired 105,820 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Conning Inc. bought a new position in Sanofi during the third quarter worth about $573,000. Cable Hill Partners LLC bought a new position in Sanofi during the third quarter worth about $228,000. Crossmark Global Holdings Inc. bought a new position in Sanofi during the third quarter worth about $4,636,000. Well Done LLC bought a new position in Sanofi during the third quarter worth about $407,000. Finally, Baldwin Brothers Inc. MA bought a new position in Sanofi during the third quarter worth about $268,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sanofi (SNY) Receives Average Recommendation of “Hold” from Analysts” was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.truebluetribune.com/2017/11/14/sanofi-sny-receives-average-recommendation-of-hold-from-analysts.html.

Shares of Sanofi (SNY) traded down 0.02% during midday trading on Friday, hitting $47.53. 2,367,326 shares of the company were exchanged. The firm has a market capitalization of $119.37 billion, a price-to-earnings ratio of 11.04 and a beta of 0.87. The firm’s 50 day moving average price is $49.39 and its 200 day moving average price is $48.42. Sanofi has a one year low of $38.40 and a one year high of $50.65.

Sanofi (NYSE:SNY) last issued its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. Analysts forecast that Sanofi will post $3.32 EPS for the current fiscal year.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply